Physician profile

Robert C Broussard

Pulmonary Disease · Lake Charles, LA

NPI 1821007170

$15,055.09

in general payments reported to CMS, 2019-2025

36 companies · $3,163 in 2025

The $3,163 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,126.98
Education$108.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $3,724.89 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Astrazeneca Pharmaceuticals LP $2,532.13 2019-2025 Fasenra, Tezspire, Breztri
Genzyme Corporation $1,087.82 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $793.01 2019-2025 Ofev, Stiolto Respimat, Spiriva Respimat
Csl Behring $786.08 2019-2025 Hizentra
Regeneron Healthcare Solutions, INC. $779.69 2019-2025 Dupixent
Grifols USA, LLC $664.60 2019-2025 Prolastin-C Liquid, Xembify
Mylan Specialty L.P. $542.72 2019-2024 Yupelri
Amgen INC. $456.78 2021-2025 Tezspire
Baxter Healthcare $453.94 2022-2025 Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care
Actelion Pharmaceuticals US, INC. $406.56 2019-2025 Opsumit, Uptravi, Opsynvi
Insmed, INC. $403.10 2020-2025 Arikayce, Brinsupri
Merck Sharp & Dohme LLC $378.79 2022-2025 Winrevair, Capvaxive, Keytruda
Viatris Specialty LLC $290.60 2025 Yupelri
Verona Pharma, INC. $200.89 2025 Ohtuvayre
Show all 36 companies
CompanyGeneral paymentsYearsTop products
United Therapeutics Corporation $195.74 2019-2024 Tyvaso
Ani Pharmaceuticals, INC. $191.36 2023-2025 Purified Cortrophin Gel
Philips North America LLC $182.02 2019-2024 (Ak6) Vest Therapy
Bayer Healthcare Pharmaceuticals INC. $181.99 2021-2023
Sanofi-Aventis U.S. LLC $122.96 2021-2023
Abiomed $121.97 2021
Novartis Pharmaceuticals Corporation $111.31 2021-2024
Genentech USA, INC. $90.06 2019-2023 Xolair
Janssen Pharmaceuticals, INC $54.07 2021-2022
Pfizer INC. $39.78 2019-2024
Takeda Pharmaceuticals U.S.A., INC. $36.75 2025 Hyqvia
Gilead Sciences, INC. $36.60 2019
Mallinckrodt Enterprises LLC $33.15 2019
Vifor Pharma, INC. $25.93 2025 Zemaira
Intuitive Surgical, INC. $25.34 2025
Circassia INC. $23.18 2020
Mallinckrodt Hospital Products INC. $17.67 2022
Electromed, INC. $16.80 2024 Smartvest
Inogen, INC. $16.55 2023 Inogen One G5 Oxygen Concentrator - Bluetooth
Advanced Respiratory, INC $15.57 2021
Tetraphase Pharmaceuticals, INC. $14.69 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert C Broussard

$15,055.09

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $3,163 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/785367/robert-c-broussard

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.